July 25, 2017 / 1:25 PM / 2 months ago

BRIEF-Resverlogix receives approval pathway from the FDA as to the inclusion of USA patients in the phase 3 betonmace trial

July 25 (Reuters) - Resverlogix Corp:

* Resverlogix receives approval pathway from the FDA as to the inclusion of usa patients in the phase 3 betonmace trial

* Resverlogix Corp - ‍receipt of a positive type c written response from division of metabolism and endocrinology products of U.S. FDA

* Resverlogix Corp- ‍agreed to make adjustments to existing betonmace study protocol and to update investigator’s brochure and informed consent documents​

* Resverlogix-FDA approval to proceed with phase 3 betonmace trial in USA well timed, should not have major impact on total duration of betonmace trial Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below